Dear Phyl, Phyllodes tumors are not staged in the same manner as breast cancer. The following information regarding phyllodes tumor is directly from the textbook “Cancer: Principles and Practice of Oncology” 6th edition, edited by DeVita,V., Hellman,S., and Rosenberg, S. I hope it is of some help to you. Beyond this, in terms of your individual case, you would need to discuss any additional interpretations with your physician.
“The term phyllodes tumor includes a group of lesions of varying
malignantCancer
Gestational trophoblastic disease
Lymphoma, malignant - ct scan
Malignant melanoma
Malignant otitis externa
Melanoma of the eye
Multiple myeloma
Skin cancer, malignant melanoma potential ranging from completely
benignBenign ear cyst or tumor
Benign positional vertigo (non-cancerous) to fully
malignantCancer
Gestational trophoblastic disease
Lymphoma, malignant - ct scan
Malignant melanoma
Malignant otitis externa
Melanoma of the eye
Multiple myeloma
Skin cancer, malignant melanoma sarcomasEwings sarcoma - x-ray
Ewing’s sarcoma
Kaposi's sarcoma - close-up
Kaposi's sarcoma - lesion on the foot
Kaposi's sarcoma - perianal
Kaposi's sarcoma on foot
Kaposi's sarcoma on the back
Kaposi's sarcoma on the thigh
Kaposi’s sarcoma
Leiomyosarcoma
Osteogenic sarcoma - x-ray.
Phyllodes tumors are classified as benign, borderline, or malignant based on the nature of the tumor margins (pushing or infiltrative) and presence of cellular atypia, mitotic activity, and overgrowth in the stroma. There is disagreement about which of these criteria is most important, although most experts favor stromal overgrowth. The percentage of phyllodes tumors classified as malignant ranges from 23% to 50%. Axillary metastases are reported in less than 5% of cases, but are a poor prognostic sign when present. Metastases more commonly follow the pattern seen with sarcomas (with lung as the most common site) and histologically resemble sarcomas. Approximately 20% of phyllodes tumors recur locally if excised with no margin or a margin of a few millimeters of normal breast tissue, regardless of whether they are benign or malignant. A wide excision with a 2cm margin of normal breast tissue is appropriate therapy for benign and borderline phyllodes tumors unless they are so large that this is not cosmetically feasible. In the past, many authors have advocated mastectomy for the management of malignant phyllodes tumors. Since phyllodes tumors are not multicentric, there is no clear-cut biologic rationale for mastectomy, and series have reported the successful treatment of malignant phyllodes tumors with wide excision. The use of systemic therapy for malignant phyllodes tumors is based on guidelines for treating sarcomas.”